Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-06
2009-12-08
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07629315
ABSTRACT:
Leptin controls the production of C-Reactive Protein (CRP), which, in turn, interacts with leptin to diminish its ability to signal satiety and reduce food intake. The interactions between leptin and CRP can be exploited to screen for agents capable of disrupting the leptin-CRP interaction, and thereby improve leptin signaling. Such agents can be used to reduce body weight, adiposity, and alleviate insulin resistance and diabetes.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 6048837 (2000-04-01), Friedman et al.
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6475984 (2002-11-01), Kirwin et al.
patent: 6777388 (2004-08-01), Grasso et al.
patent: 6849714 (2005-02-01), Bridon et al.
patent: 2002/0037553 (2002-03-01), Al-Barazanji et al.
patent: 2002/0107211 (2002-08-01), Friedman et al.
patent: 2005/0038609 (2005-02-01), Benner
patent: 2005/0250690 (2005-11-01), Gonzalez et al.
patent: 0 154 316 (1985-09-01), None
patent: 0 401 384 (1989-12-01), None
patent: WO 90/14363 (1990-11-01), None
patent: WO 93/05722 (1993-04-01), None
patent: WO 95/34670 (1995-12-01), None
patent: WO 96/23520 (1996-08-01), None
patent: WO 96/31526 (1996-10-01), None
patent: WO 96/35787 (1996-11-01), None
patent: WO 96/41865 (1996-12-01), None
patent: WO 97/06816 (1997-02-01), None
patent: WO 97/16550 (1997-05-01), None
patent: WO 97/31898 (1997-09-01), None
patent: WO 97/31899 (1997-09-01), None
patent: WO 97/46585 (1997-12-01), None
Campfield et al., Science 280: 1383-1387, 1998.
Grasso et al., Endocrinol. 138: 1413-1418, 1997.
Jeffrey M. Friedman et al., “Leptin and the regulation of body weight in mammals”, Nature, vol. 395, Oct. 22, 1998, p. 763-770.
Rexford S. Ahima et al., “Leptin”, Annu. Rev. Physiol., 2000, 62:413-437.
Yiying Zhang et al., “Positional cloning of the mouse obese gene and its human homologue”, Nature, vol. 372, Dec. 1, 1994, pp. 425-432.
Gwo-Hwa Lee et al., “Abnormal splicing of the leptin receptor in diabetic mice”, Nature, vol. 379, Feb. 15, 1996, pp. 632-635.
Amy H. Luke et al., “Leptin and body composition of Nigerians, Jamaicans and US Blacks1-3” Am J. Clin Nutr. 1998: 67:391-396.
Peter J. Havel, “Leptin productin and action: relevance to energy balance in humans1-3”, Am J Clin Nutr 1998; 67:35-356.
Steven B. Heymsfield et al., “Recombinant Leptin for Weight Loss in Obese and Lean Adults”, Jama, Oct. 27, 1999—vol. 282, No. 16, pp. 1568-1575.
Christian Bjorbaek et al., “The Role of SOCS-3 in Leptin Signaling and Leptin Resistance”, The Journal of Biological Chemistry, vol. 274, No. 42, Oct. 15, 1999, pp. 30059-30065.
Zhuowei Wang et al., “Leptin Resistance of Adipocytes in Obesity: Role of Suppressors of Cytokine Signaling”, Biochemical and Biophysical Research Communications, 277, 20—26, 2000.
Michael W. Schwartz et al., “Cerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in humans”, Nature Medicine, vol. 2, No. 5, May 1996, pp. 589-593.
M. Maachi et al., “Systemic low-grade inflammation is related to both circulating and adiopose tissue TNFα, leptin and IL-6 levels in obese women”, International Journal of Obesity (2004) 28, 993-997.
Trisha Gura, “Leptin Not Impressive in Clinical Trial”, Science, vol. 286, Oct. 29, 1999, pp. 881-882.
James T. Willerson MD et al., “Inflammation as a Cardiovascular Risk Factor”, Circulation Jun. 1, 2004, pp. II-2-II-10.
Matthias B. Shulze et al., “C-Reactive Protein and Incident Cardiovascular Events Among Men with Diabetes”, Diabetes Care, vol. 27, No. 4, Apr. 2004, pp. 889-894.
Anna U. Bielinska et al., “DNA Complexing with Polyamidoamine Dendrimers: Implications for Transfection”, Bioconjugate Chem. 1999, 10, 843-850.
Tsutomu Kazumi et al., “C-Reactive Protein in Young, Apparently Healthy Men: Associations With Serum Leptin, QTc Interval, and High-Density Lipoprotein-Cholesterol”, Metabolism, vol. 52, No. 9, Sep. 2003, pp. 1113-1116.
Paul M. Ridker MD et al., “High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practive to clinical benefit”, American Heart Journal Jul. 2004, pp. 519-526.
Goran Rajs et al., “C-Reactive Protein Concentrations in Cerebral Spinal Fluid in Gram-Positive and Gram-Negative Bacterial Meningitis”, Clinical Chemistry, 48, No. 3, 2003, pp. 591-592.
Jonas Emsley et al., “Structure of pentameric human serum amyloid P component”, Nature, vol. 367, Jan. 27, 1994, pp. 338-345.
M. J. Roberts et al., “Chemistry for peptide and protein PEGylation”, Advanced Drug Delivery Reviews 54 (2002) 459-476.
M. Friedman-Einat et al., “Serum leptin activity in obese and lean patients”, Regulatory Peptides, 111 (2003) 77-82.
Hebok Song et al., “In vitro mortility of AtKCBP, a calmodulin-binding kinesin protein of Arabidopsis” Proc. Natl. Acac. Sci. USA, vol. 94, pp. 322-327, Jan. 1997.
Jing-Ning Huan et al., “Adipocyte-selective Reduction of the Leptin Receptors Induced by Antisense RNA Leads to Increased Adiposity, Dyslipidemia, and Insulin Resistance”, The Journal of Biological Chemistry, vol. 278, No. 46, Issue of Nov. 14, 2003, pp. 45638-45650.
P. Mistrik et al., “BiaCore analysis of leptin-leptin receptor interaction: evidence for 1:1 stoichiometry”, Analytical Biochemistry, 327 (2004) 271-277.
F.C. De Beer et al., “Isolation and characterization of C-reactive protein and serum amyloid P component in the rat”, Immunology 1982, 45, 55-70.
Christian Vaisse et al., “Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice”, Natural Genetics, vol. 14, Sep. 1996, pp. 95-97.
Allan Z. Zhao et al., “A phosphatidylinositol 3-kinase—phosphodiesterase 3B-cyclc AMP pathway in hypothalamic action of leptin on feeding”, Nature Neuroscience, vol. 5, No. 8, Aug. 2002, pp. 727-728.
Kevin D. Niswender et al., “Key enzyme in leptin-induced anorexia”, Nature, vol. 413, Oct. 25, 2001, pp. 794-795.
F.L. Graham et al., “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA”, Virology 52, 456-467 (1973).
John Devereux et al., “A comprehensive set of sequence analysis programs for the VAX”, Nucleic Acids Research, vol. 12, No. 1, 1984, pp. 387-395.
Humberto Carrillo et al., “The Multiple Sequence Alignment Problem in Biology”, Siam J. Appl. Math. vol. 48, No. 5, Oct. 1988, pp. 1073-1082.
Gilbert Chu et al., “SV40 DNA transfection of cells in suspension: analysis of the efficiency of transcription and translation of T-antigen”, Gene, 13, (1981) 197-202.
Margaret L.M. Anderson et al., “Quantitative Filter Hybridisation—Chapter 4”, Nucleic acid hyridisation a practical approach, 1985, pp. 73-111.
Stephen Altschul et al., “Basic Local Alignment Search Tool”, J. Mol. Biol. (1990) 215, 403-410.
Joachim W. Engels et al., “Gene Synthesis”, Angew. Chem. Int. Ed. Engl. 28, (1989) 716-734.
Paul A. Kitts et al., “A Method for Producing Recombinant Baculovirus Expression Vectors at High Frequency”, BioTechniques vol. 14, No. 5 (1993), pp. 810-817.
Verne A. Luckow et al., “Baculovirus systems for the expression of human gene products”, Current Opinion in Biotechnology, 1993, 4: 564-572.
Verne A. Luckow et al., “Efficient Generation of Infectious Recombinant Baculoviruses by Site-Specific Transposon-Mediated Insertion of Foreign Genes into a Baculovirus Genome Propagated inEscherichia coli”, Journal of Virology, vol. 67, No. 8, Aug. 1993, pp. 4566-4579.
Christophe Benoist et al., “In vivo sequence requirements of the SV40 early promoter region”, Nature, vol. 290, Mar. 26, 1981, pp. 304-310.
Tadashi Yamamoto
Bent Stephen A.
Chandra Gyan
Foley & Lardner LLP
Landsman Robert
University of Pittsburgh of the Commonwealth System of Higher Ed
LandOfFree
Compositions for blocking the inhibitory effect of human CRP... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for blocking the inhibitory effect of human CRP..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for blocking the inhibitory effect of human CRP... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4140246